MAP BioPharma responds to NICE consultation on proposed changes to the technology appraisals programme
MAP BioPharma has submitted a written response to the National Institute for Health and Care Excellence (NICE) 6 week public consultation on proposed amendments to the technology appraisal (TA) process.
NICE is proposing amendments to the TA process to enable more topics to be processed through the current 4 appraisal committees. Increasing demand means that the current appraisal process will be unable to cope with the number of appraisals the Institute will be asked to undertake, within the next two years. The proposed adjustments are intended to retain the familiar elements of the current single technology appraisals (STA), while aligning them more efficiently.